Search research articles
Contact Us
Filters
Showing results (131-140 of 144) with videos related to
Page
of 15
Sort By:
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]
Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
World Journal of Gastroenterology
|
March 31, 2018
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
Lai Wei, Fu-Sheng Wang, Ming-Xiang Zhang, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Journal of Clinical and Translational Hepatology
|
September 15, 2025
Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model
Rong Fan, Ya-Ru Shi, Lei Chen, et al.
Journal of Gastroenterology and Hepatology
|
January 31, 2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China
Lai Wei, Qing Xie, Jin Lin Hou, et al.
Hepatology International
|
August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Zoological Research
|
March 30, 2023
Cell atlas of CCl <sub>4</sub>-induced progressive liver fibrosis reveals stage-specific responses
Peng-Cheng Guo, Jing Zuo, Ke-Ke Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries
Jin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Plos One
|
June 9, 2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data
Guo-Feng Chen, Lai Wei, Jing Chen, et al.
The Lancet. Gastroenterology & Hepatology
|
December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei, Seng Gee Lim, Qing Xie, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 144) with videos related to
Sort By:
Page
of 15
Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|
May 26, 2007
[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52]
Ji-dong Jia, Jin-lin Hou, You-kuan Yin, et al.
World Journal of Gastroenterology
|
March 31, 2018
Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
Lai Wei, Fu-Sheng Wang, Ming-Xiang Zhang, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Journal of Clinical and Translational Hepatology
|
September 15, 2025
Hepatocellular Carcinoma Risk Stratification for Cirrhosis Patients: Integrating Radiomics and Deep Learning Computed Tomography Signatures of the Liver and Spleen into a Clinical Model
Rong Fan, Ya-Ru Shi, Lei Chen, et al.
Journal of Gastroenterology and Hepatology
|
January 31, 2018
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China
Lai Wei, Qing Xie, Jin Lin Hou, et al.
Hepatology International
|
August 24, 2021
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Zoological Research
|
March 30, 2023
Cell atlas of CCl <sub>4</sub>-induced progressive liver fibrosis reveals stage-specific responses
Peng-Cheng Guo, Jing Zuo, Ke-Ke Huang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
July 16, 2019
Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries
Jin-Lin Hou, Wei Zhao, Changhyeong Lee, et al.
Plos One
|
June 9, 2016
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data
Guo-Feng Chen, Lai Wei, Jing Chen, et al.
The Lancet. Gastroenterology & Hepatology
|
December 18, 2018
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei, Seng Gee Lim, Qing Xie, et al.
Page
of 15